分子靶向药物联合TACE在肝癌治疗中的进展

Progress of molecular targeted therapy combined TACE of hepatocellular carcinoma

对于那些已经不适宜手术切除的中晚期肝细胞肝癌(HCC),单纯的经动脉化疗栓塞(TACE)显然并不能明显改善患者的预后,但是随着分子靶向药物的面世,使得HCC的治疗有了新的治疗方案。在治疗HCC的临床试验当中,血管内皮生长抑制剂、多靶点抑制剂、小分子酪氨酸激酶抑制剂以及分子靶向药与TACE的联合已经显示出了潜在的疗效和良好的发展前景。本文对使用血管内皮生长抑制剂、多靶点抑制剂等联合TACE治疗HCC的临床研究现状进行综述。

For those who have not appropriate surgical removal of the middle-late hepatocellular carcinoma（HCC）, simply by transcatheter arterial chemoembolization（TACE） with conventional treatment can not obviously improve the prognosis of patients.The emergence of molecular targeted drugs to treat hepatocellurlar carcinoma provides a new idea. Molecular targeted drugs in the treatment of HCC clinical trails including multiple targets inhibitors, and the targeted molecular medicine combined with TACE has shown the potential curative effect and good prospects for development.We summarize the using multiple targets inhibitors, vascular endothelial growth inhibitor combined with TACE to HCC.